Showing results (61-70 of 211) with videos related to

Sort By:
Pageof 22
Journal of Clinical Pathology|January 11, 2011
Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasmsLeonardo Boiocchi, Claudia Vener, Federica Savi, et al.
American Journal of Hematology|June 11, 2026
Clinical and Laboratory Characterization of Acquired Von Willebrand SyndromeAlessandro Ciavarella, Luciano Baronciani, Omid Seidizadeh, et al.
Hematological Oncology|October 7, 2015
Oxidative status in treatment-naïve essential thrombocythemia: a pilot study in a single centerAlessandra Iurlo, Rachele De Giuseppe, Mariarita Sciumè, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|December 2, 2025
The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysisValentina Biagioli, Alessandro Inzoli, Antonella Barone, et al.
American Journal of Clinical Pathology|August 15, 2008
The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemiaUmberto Gianelli, Alessandra Iurlo, Claudia Vener, et al.
Oncotarget|September 18, 2015
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?Alessandra Iurlo, Emanuela Orsi, Daniele Cattaneo, et al.
Cancers|April 12, 2022
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary MyelofibrosisDaniele Cattaneo, Claudia Vener, Elena Maria Elli, et al.
Cancer Medicine|April 23, 2020
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)Massimo Breccia, Pier Paolo Olimpieri, Odoardo Olimpieri, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 1, 2017
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerationsUmberto Gianelli, Daniele Cattaneo, Anna Bossi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2016
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerationsUmberto Gianelli, Daniele Cattaneo, Anna Bossi, et al.
Pageof 22